← Leaderboards
Eric T. Kimchi
Pennsylvania State Univ Hershey Med Ctr
$462
Attributed
$462
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $462 · FY2009–22$500$375$250$125$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$462 · 1
VA$0 · 1
By mechanism
M01$462 · 1
I01$0 · 1
Top collaborators
- Kevin Finnbar Staveleyo'Carroll4 shared
Most similar at Pennsylvania State Univ Hershey Med Ctr
Same institution · by research overlap
- Mark Kester$13,621,664
- Kevin Finnbar Staveleyo'carroll$5,239,458
- Gavin P. Robertson$6,707,206
- James R Connor$11,507,520
- David F Claxton$3,137,698
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorAnimal ModelMediatingTumor ProgressionChemotherapyFundingIncidenceMalignant NeoplasmsResearch PersonnelUnited States National Institutes Of HealthReceptorPrimary Carcinoma Of The Liver CellsBaseLiver DiseasesCardiacCancer TypeCancer TherapyCancer PatientAnti-Tumor Immune ResponseAntibodiesClinically RelevantClinical ApplicationClinical PracticeCancer Initiation
Grant awards (5)
Building a New Therapeutic Paradigm for Hepatocellular Cancer by Dissecting the Interaction between Radiofrequency Ablation, Chemotherapy, and Immunotherapy$0
I01 · FY2022 · VA · contact PI
Building a New Therapeutic Paradigm for Hepatocellular Cancer by Dissecting the Interaction between Radiofrequency Ablation, Chemotherapy, and Immunotherapy$0
I01 · FY2021 · VA · contact PI
Building a New Therapeutic Paradigm for Hepatocellular Cancer by Dissecting the Interaction between Radiofrequency Ablation, Chemotherapy, and Immunotherapy$0
I01 · FY2020 · VA · contact PI
Building a New Therapeutic Paradigm for Hepatocellular Cancer by Dissecting the Interaction between Radiofrequency Ablation, Chemotherapy, and Immunotherapy$0
I01 · FY2019 · VA · contact PI
CLINICAL TRIAL: UNRESECTABLE HEPATOCELLULAR CA WITH OGF: A PHASE I STUDY$462
M01 · FY2009 · RR · contact PI